Cidara Theraptcs Stock Price, News & Analysis

Cidara Therapeutics (NASDAQ: CDTX) will present new clinical data at the 10th Congress on Trends in Medical Mycology (TIMM) from October 8-11, 2021, in Aberdeen, Scotland. The focus is on rezafungin, a once-weekly echinocandin in Phase 3 trials for serious fungal infections. Top-line data from the Phase 3 ReSTORE trial is expected by the end of 2021, with a New Drug Application (NDA) anticipated in mid-2022. Key presentations include safety and pharmacokinetics in hepatic impairment and post-antifungal effects against various Candida species.

Cidara Therapeutics (NASDAQ: CDTX) announced its participation in IDWeek from September 29 to October 3, 2021, where it will present new data on rezafungin, a novel once-weekly echinocandin in Phase 3 trials for serious fungal infections. The presentations will cover clinical safety in patients with hepatic impairment and the efficacy of rezafungin against invasive fungal isolates. Top-line data from the Phase 3 ReSTORE trial is expected by year-end 2021, with a New Drug Application (NDA) filing anticipated in mid-2022.

SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, a biotechnology company focused on long-acting therapeutics, announced that CEO Jeffrey Stein will participate in two upcoming investor conferences. The H.C. Wainwright 23rd Annual Global Investment Conference will feature a presentation available from 7:00 AM ET on September 13, 2021. The Cantor Global Healthcare Conference is scheduled for September 28, 2021, at 10:40 AM ET. Both presentations can be accessed on the company's website. Cidara is developing treatments for fungal and viral infections.

Cidara Therapeutics (NASDAQ: CDTX) is hosting a webinar on September 21, 2021, from 10am to 12pm ET, focusing on the Cloudbreak® platform and the commercial prospects for rezafungin.

Clinical experts will address the increasing risks of invasive fungal infections in cancer patients and discuss unmet needs in respiratory viral diseases.

The event will feature updates on rezafungin's late-stage development, and its potential role in treating candidemia and preventing infections in immunocompromised patients.

Cidara Therapeutics announced key management appointments, bringing in Preetam Shah, Ph.D., MBA, as Chief Financial Officer and Chief Business Officer, and Shane Ward as Chief Legal Officer and Corporate Secretary. Both bring over 20 years of biotech experience. The company is poised for significant milestones, including top-line data from the pivotal Phase 3 ReSTORE trial of its antifungal candidate, rezafungin, expected by year-end. Inducement awards were granted to Shah and Ward under the 2020 Inducement Incentive Plan, with options covering a total of 561,850 shares.

Cidara Therapeutics has successfully completed recruitment for its pivotal Phase 3 ReSTORE trial, evaluating rezafungin as a potential first-line treatment for candidemia and invasive candidiasis. The trial involved 184 patients, addressing a significant unmet medical need with mortality rates as high as 40%. Top-line data is expected by the end of 2021, with an NDA filing anticipated in mid-2022. Rezafungin aims to offer a once-weekly treatment option for critically ill patients, with Mundipharma responsible for international distribution.

Cidara Therapeutics, Inc. (NASDAQ: CDTX) reported strong Q2 2021 financial results, with revenue of $32.9 million, up from $3.4 million in Q2 2020, largely attributed to a collaboration with Janssen. The company ended Q2 with $53.1 million in cash. Notably, Cidara achieved a net income of $10.7 million in Q2 2021, a significant turnaround from a net loss of $18.3 million the previous year. They anticipate filing an IND for lead candidate CD388 by year-end and report ongoing Phase 3 trials for rezafungin, expecting top-line data availability by year's end.

Cidara Therapeutics (NASDAQ: CDTX) announced that its President and CEO, Jeffrey Stein, Ph.D., will participate in a panel discussion at the 2021 Wedbush PacGrow Healthcare Conference on August 11, 2021, at 4:40 PM ET. The event will feature a live audio webcast available on the company's website. Cidara focuses on developing long-acting therapeutics for serious fungal and viral infections, highlighting its lead antifungal candidate, rezafungin, and its antiviral platform, Cloudbreak®.

Cidara Therapeutics (NASDAQ: CDTX) announced presentations of clinical data on rezafungin at the ISHAM Asia Congress from August 6-8, 2021. Rezafungin, a novel once-weekly echinocandin, aims to treat and prevent serious fungal infections. The presentations will include updated findings from the Phase 2 STRIVE study and activity analysis against Candida and Aspergillus spp. isolates from Asia-Pacific. The Chief Medical Officer, Taylor Sandison, will lead these discussions, showcasing the progress of the ongoing Phase 3 trials.